Antisense oligonucleotide suppression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis

References

• Husebekk A, Skogen B, Husby G, Marhaug G. Transformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivo. Scand J Immunol 1985;21:283–287.
   PubMed Web of Science ®Google Scholar
• Tape C, Tan R, Nesheim M, Kisilevsky R. Direct evidence for circulating apoSAA as the precursor of tissue AA amyloid deposits. Scand J Immunol 1988;28:317–324.
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361–2371.
   PubMed Web of Science ®Google Scholar
• Obici L, Raimondi S, Lavatelli F, Bellotti V, Merlini G. Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 2009;61:1435–1440.
   PubMed Web of Science ®Google Scholar
• van der Hilst JC, Simon A, Drenth JP. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005;5:87–98.
   PubMed Web of Science ®Google Scholar
• Verine J, Mourad N, Desseaux K, Vanhille P, Noël LH, Beaufils H, Grateau G, et al. Clinical and histological characteristics of renal AA amyloidosis: a retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response. Hum Pathol 2007;38:1798–1809.
   PubMed Web of Science ®Google Scholar
• Koivuniemi R, Paimela L, Suomalainen R, Leirisalo-Repo M. Amyloidosis as a cause of death in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008;26:408–413.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24–29.
   PubMed Web of Science ®Google Scholar
• Ganapathi MK, Rzewnicki D, Samols D, Jiang SL, Kushner I. Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in Hep 3B cells. J Immunol 1991;147:1261–1265.
   PubMed Web of Science ®Google Scholar
• Betts JC, Cheshire JK, Akira S, Kishimoto T, Woo P. The role of NF-kappa B and NF-IL6 transactivating factors in the synergistic activation of human serum amyloid A gene expression by interleukin-1 and interleukin-6. J Biol Chem 1993;268:25624–25631.
   PubMed Web of Science ®Google Scholar
• Jiang SL, Lozanski G, Samols D, Kushner I. Induction of human serum amyloid A in Hep 3B cells by IL-6 and IL-1 beta involves both transcriptional and post-transcriptional mechanisms. J Immunol 1995;154:825–831.
   PubMedGoogle Scholar
• Benditt EP, Eriksen N, Hanson RH. Amyloid protein SAA is an apoprotein of mouse plasma high density lipoprotein. Proc Natl Acad Sci USA 1979;76:4092–4096.
   PubMed Web of Science ®Google Scholar
• De Beer FC, Mallya RK, Fagan EA, Lanham JG, Hughes GR, Pepys MB. Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982;2:231–234.
   PubMed Web of Science ®Google Scholar
• Röcken C, Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch 2002;440:111–122.
   PubMed Web of Science ®Google Scholar
• Maury CP, Liljeström M, Laiho K, Tiitinen S, Kaarela K, Hurme M. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis. Arthritis Rheum 2003;48:3068–3076.
   PubMed Web of Science ®Google Scholar
• Touitou I, Sarkisian T, Medlej-Hashim M, Tunca M, Livneh A, Cattan D, Yalçinkaya F, et al.; International Study Group for Phenotype-Genotype Correlation in Familial Mediterranean Fever. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 2007;56:1706–1712.
   PubMed Web of Science ®Google Scholar
• Maury CP, Aittoniemi J, Tiitinen S, Laiho K, Kaarela K, Hurme M. Variant mannose-binding lectin 2 genotype is a risk factor for reactive systemic amyloidosis in rheumatoid arthritis. J Intern Med 2007;262:466–469.
   PubMed Web of Science ®Google Scholar
• Westermark P, Westermark GT. Review. Reflections on amyloidosis in Papua New Guinea. Philos Trans R Soc Lond, B, Biol Sci 2008;363:3701–3705.
   PubMedGoogle Scholar
• Moriguchi M, Terai C, Koseki Y, Uesato M, Nakajima A, Inada S, Nishinarita M, et al. Influence of genotypes at SAA1 and SAA2 loci on the development and the length of latent period of secondary AA-amyloidosis in patients with rheumatoid arthritis. Hum Genet 1999;105:360–366.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Higashi S, Tomoda K, Tsukano M, Baba S, Shono M. Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis. Rheumatology (Oxford) 2006;45:43–49.
   PubMed Web of Science ®Google Scholar
• Sipe JD, McAdam KP, Uchino F. Biochemical evidence for the biphasic development of experimental amyloidosis. Lab Invest 1978;38:110–114.
   PubMed Web of Science ®Google Scholar
• Kisilevsky R, Boudreau L. Kinetics of amyloid deposition. I. The effects of amyloid-enhancing factor and splenectomy. Lab Invest 1983;48:53–59.
   PubMed Web of Science ®Google Scholar
• Skinner M, Shirahama T, Benson MD, Cohen AS. Murine amyloid protein AA in casein-induced experimental amyloidosis. Lab Invest 1977;36:420–427.
   PubMed Web of Science ®Google Scholar
• Kisilevsky R. Preparation and propagation of amyloid-enhancing factor. Methods Mol Biol 2005;299:237–241.
   PubMedGoogle Scholar
• Nakamura T. Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis. Mod Rheumatol 2008;18:109–118.
   PubMed Web of Science ®Google Scholar
• Dember LM, Hawkins PN, Hazenberg BP, Gorevic PD, Merlini G, Butrimiene I, Livneh A, et al.; Eprodisate for AA Amyloidosis Trial Group. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007;356:2349–2360.
   PubMed Web of Science ®Google Scholar
• Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010;468:93–97.
   PubMed Web of Science ®Google Scholar
• Thomas T, Ginsberg H. Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia. Curr Atheroscler Rep 2010;12:58–65.
   PubMed Web of Science ®Google Scholar
• Geary RS. Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol 2009;5:381–391.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Migita S. Complete primary structures of two major murine serum amyloid A proteins deduced from cDNA sequences. Proc Natl Acad Sci USA 1985;82:2915–2919.
   PubMed Web of Science ®Google Scholar
• Schägger H, von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem 1987;166:368–379.
   PubMed Web of Science ®Google Scholar
• Westermark GT, Johnson KH, Westermark P. Staining methods for identification of amyloid in tissue. Meth Enzymol 1999;309:3–25.
   PubMed Web of Science ®Google Scholar
• Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010;50:259–293.
   PubMed Web of Science ®Google Scholar
• Hatanaka E, Monteagudo PT, Marrocos MS, Campa A. Interaction between serum amyloid A and leukocytes - a possible role in the progression of vascular complications in diabetes. Immunol Lett 2007;108:160–166.
   PubMed Web of Science ®Google Scholar
• He RL, Zhou J, Hanson CZ, Chen J, Cheng N, Ye RD. Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2. Blood 2009;113:429–437.
   Web of Science ®Google Scholar
• Song C, Hsu K, Yamen E, Yan W, Fock J, Witting PK, Geczy CL, Freedman SB. Serum amyloid A induction of cytokines in monocytes/macrophages and lymphocytes. Atherosclerosis 2009;207:374–383.
   PubMed Web of Science ®Google Scholar
• Sewell KL, Geary RS, Baker BF, Glover JM, Mant TG, Yu RZ, Tami JA, Dorr FA. Phase I trial of ISIS 104838, a 2’-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther 2002;303:1334–1343.
   PubMed Web of Science ®Google Scholar
• Chia S, Dent S, Ellard S, Ellis PM, Vandenberg T, Gelmon K, Powers J, et al. Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clin Cancer Res 2009;15:708–713.
   PubMed Web of Science ®Google Scholar
• Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, et al. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol 2009;27:4741–4746.
   PubMed Web of Science ®Google Scholar
• Akdim F, Stroes ES, Sijbrands EJ, Tribble DL, Trip MD, Jukema JW, Flaim JD, Su J, Yu R, Baker BF, Wedel MK, Kastelein JJ. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. Am J Coll Cardiol 2010;55:1611–1618.
   PubMed Web of Science ®Google Scholar
• Raab R, Sparano JA, Ocean AJ, Christos P, Ramirez M, Vinciguerra V, Kaubisch A. A phase 1 trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction and gastric carcinoma. Am J ClinOncol 2010;33:61–65.
   Google Scholar
• Yu RZ, Zhang H, Geary RS, Graham M, Masarjian L, Lemonidis K, Crooke R, et al. Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice. J Pharmacol Exp Ther 2001;296:388–395.
   PubMed Web of Science ®Google Scholar
• Yu RZ, Lemonidis KM, Graham MJ, Matson JE, Crooke RM, Tribble DL, Wedel MK, et al. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol 2009;77:910–919.
   PubMed Web of Science ®Google Scholar